Zilurgisertib

Zilurgisertib (INCB-000928; NBU-928) is a selective ALK2 inhibitor with an IC50 value of 15 nM. Zilurgisertib inhibits SMAD1/5 phosphorylation with an IC50 value of 63 nM. Zilurgisertib inhibits hepcidin production and improve anemia. Zilurgisertib can be used in melanoma research[1][2].

Product Specifications

CAS Number

[2173389-57-4]

Product Name Alternative

INCB-000928; NBU-928

UNSPSC

12352005

Target

TGF-β Receptor

Type

Reference compound

Related Pathways

TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/zilurgisertib.html

Purity

98.25

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(C2=CC=C(C=C2)[C@]3(CN(C4CCOCC4)C5)[C@]5([H])C3)=CN=C1N)NC(CC6)(CC7)CCC67O

Molecular Formula

C30H38N4O3

Molecular Weight

502.65

References & Citations

[1]Li J, et al. Preparation of aminopyridine derivatives and their use as selective ALK-2 inhibitors. WO2018014829 A1.|[2]Stubbs M C, et al. ALK2 and JAK2 inhibition for improved treatment of anemia in myelofibrosis patients: Preclinical profile of an ALK2 inhibitor Zilurgisertib in combination with Ruxolitinib. Blood, 2023, 142: 1789.